Story Killed - Unable to Verify FDA Approval Claims

**EDITOR'S NOTE: This story has been killed due to inability to verify the claimed FDA approval.**

After editorial review, we cannot confirm that the FDA has actually approved a 7.2mg dose of Wegovy (semaglutide) for weight loss as described in the original source material. The claims about "Wegovy HD" and triple-strength dosing could not be substantiated through official FDA channels or verified MedPage Today reporting.

Responsible health journalism requires verification of regulatory approvals before publication, as unconfirmed drug approval claims can mislead patients and healthcare providers about available treatment options.

Weight Index maintains strict editorial standards requiring multiple source verification for all regulatory approval stories. We will monitor official FDA communications and verified medical news sources for any legitimate developments regarding higher-dose semaglutide approvals for obesity treatment.

Readers seeking current information about approved Wegovy dosing should consult the official FDA prescribing information, which currently lists 2.4mg weekly as the maximum approved dose for weight management in adults with obesity or overweight with comorbidities.